Shares of Derma Sciences Inc. (NASDAQ:DSCI) rose 2.6% on Thursday . The stock traded as high as $4.04 and last traded at $4.01, with a volume of 121,827 shares. The stock had previously closed at $3.91.

The firm has a 50 day moving average of $3.98 and a 200 day moving average of $3.62. The firm’s market cap is $105.36 million.

Derma Sciences (NASDAQ:DSCI) last released its quarterly earnings data on Wednesday, May 11th. The company reported ($0.07) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.13) by $0.06. The business earned $20.20 million during the quarter, compared to the consensus estimate of $20.60 million. Equities analysts forecast that Derma Sciences Inc. will post ($0.20) EPS for the current year.

A hedge fund recently raised its stake in Derma Sciences stock. Jennison Associates LLC raised its stake in Derma Sciences Inc. (NASDAQ:DSCI) by 22.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,407,506 shares of the company’s stock after buying an additional 261,818 shares during the period. Jennison Associates LLC owned 5.45% of Derma Sciences worth $6,432,000 at the end of the most recent quarter.

Derma Sciences, Inc (Derma Sciences) is a tissue regeneration company, which is engaged in the research and management of acute and chronic wounds, and burns. The Company operates through three segments: pharmaceutical wound care, advanced wound care and traditional wound care products. Pharmaceutical wound care products consist of DSC127, a product for the treatment of a variety of dermal applications, including diabetic foot ulcers and scar prevention.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.